THE USE OF ACTOVEGIN FOR PREVENTION OF POST-STROKE COGNITIVE IMPAIRMENT


DOI: https://dx.doi.org/10.18565/pharmateca.2018.5.66-70

E.A. Koltsova (1, 2)

1) FSBEI HE RNSMU n.a. N.I. Pirogov of RMH, Moscow, Russia; 2) SRI of Cerebrovascular Pathology and Stroke, Moscow, Russia
Stroke remains one of the most common causes of death worldwide and the third most important cause of disability. Post-stroke cognitive impairment (PSCI) of varying severity is detected in 40–70% of stroke patients. Cognitive impairment slows the process of functional recovery after a stroke. One of the most promising areas in the treatment of PSCI is the use of drugs with neurotrophic action. A large international, randomized, placebo-controlled ARTEMIS study has been devoted to the evaluation of the efficacy of actovegin in PSCI. The study found a statistically significant difference in the primary endpoint, a change in the ADAS-Cog + score at 6 months of treatment in the Actovegin group compared to placebo, indicating the effectiveness of the drug in improving cognitive function in stroke patients. Based on the results of an international randomized placebo-controlled ARTEMIS study, it can be concluded that the use of Actovegin in patients with acute ischemic stroke improves the prognosis for the recovery of cognitive functions, and, consequently, the prognosis of all rehabilitation activities conducted in both acute and early recovery period of stroke.

About the Autors


Corresponding author: E.A. Koltsova – RNSMU n.a. N.I. Pirogov of RMH, SRI of Cerebrovascular Pathology and Stroke; Moscow, Russia; e-mail: koltsovaevgenia@rambler.ru


Similar Articles


Бионика Медиа